EFFECTS OF PSILOCYBIN IN TERMINAL CANCER PATIENTS WITH ANXIETY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这是一项临床研究，重点是管理身体和心理症状，以提高接近生命尽头的个人的生活质量。具体目的是了解致幻剂psilocybin是否可以有效减少焦虑，抑郁和身体疼痛，并改善晚期癌症患者的生活质量。将筛选12例预计生存期长达1年的癌症和焦虑症成人受试者，并给予知情同意。本初步研究是一项交叉设计的双盲、安慰剂对照研究。所有受试者将在一次治疗期间接受0.2 mg/kg的裸盖菇素，并在六周后的第二次治疗期间接受250 mg烟酸的活性安慰剂。主要研究者和一名硕士水平的精神治疗师或护士将留在受试者身边，直到药物的影响消退。将通过检查焦虑、抑郁、疼痛和生活质量的各种治疗前和治疗后措施来评价疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a clinical study focused on management of physical and psychological symptoms to enhance the quality of life remaining for individuals who are nearing the end of their lives. The specific aim is to learn whether the hallucinogen, psilocybin, might be effective in reducing anxiety, depression and physical pain, and improving the quality of life in terminal cancer patients. 12 adult subjects with cancer with projected survival up to one year and anxiety disorder will be screened and given informed consent. This pilot investigation is a double-blind, placebo-controlled study with a crossover design. All subjects will receive 0.2 mg/kg of psilocybin during one treatment session and an active placebo, 250 mg of niacin, during a second session six weeks later, in a randomized sequence. The principal investigator and a master's level psychoterapist or nurse will remain with the subject until the effects of the drug have subsided. Efficacy will be evaluated by a variety of pre- and post-measures examining anxiety, depression, pain and quality of life.